BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22345044)

  • 1. Low trough serum infliximab and antibodies to infliximab in smokers.
    Kong JY; Bundell C; Pawlik J; Hollingsworth P; Forbes G
    Inflamm Bowel Dis; 2013 Mar; 19(3):E35-6. PubMed ID: 22345044
    [No Abstract]   [Full Text] [Related]  

  • 2. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.
    Ungar B; Chowers Y; Yavzori M; Picard O; Fudim E; Har-Noy O; Kopylov U; Eliakim R; Ben-Horin S;
    Gut; 2014 Aug; 63(8):1258-64. PubMed ID: 24041539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
    Marits P; Landucci L; Sundin U; Davidsdottir L; Nilsson J; Befrits R; Wikström AC; Eberhardson M
    J Crohns Colitis; 2014 Aug; 8(8):881-9. PubMed ID: 24486178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA
    Scand J Gastroenterol; 2011 Mar; 46(3):310-8. PubMed ID: 21087119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease.
    Grosen A; Julsgaard M; Kelsen J; Christensen LA
    J Crohns Colitis; 2014 Feb; 8(2):175-6. PubMed ID: 24090905
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD.
    Zitomersky NL; Atkinson BJ; Fournier K; Mitchell PD; Stern JB; Butler MC; Ashworth L; Hauenstein S; Heiner L; Chuang E; Singh S; Bousvaros A
    Inflamm Bowel Dis; 2015 Feb; 21(2):307-14. PubMed ID: 25569737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity to infliximab is associated with HLA-DRB1.
    Billiet T; Vande Casteele N; Van Stappen T; Princen F; Singh S; Gils A; Ferrante M; Van Assche G; Cleynen I; Vermeire S
    Gut; 2015 Aug; 64(8):1344-5. PubMed ID: 25876612
    [No Abstract]   [Full Text] [Related]  

  • 9. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.
    Seow CH; Newman A; Irwin SP; Steinhart AH; Silverberg MS; Greenberg GR
    Gut; 2010 Jan; 59(1):49-54. PubMed ID: 19651627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inflammatory diseases of the intestines].
    Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
    Rev Med Suisse; 2006 Jan; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
    Bond A; Asher R; Jackson R; Sager K; Martin K; Kneebone A; Philips S; Taylor W; Subramanian S
    Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.
    Gils A; Van Stappen T; Dreesen E; Storme R; Vermeire S; Declerck PJ
    Inflamm Bowel Dis; 2016 Apr; 22(4):969-75. PubMed ID: 26954707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of pneumonia among patients with inflammatory bowel disease: a comparison between patients treated with biologic therapies and with conventional drugs.
    Romano C; Sinagra E; Criscuoli V; Orlando A; Maisano S; Cottone M
    J Crohns Colitis; 2013 Oct; 7(9):e405-6. PubMed ID: 23764367
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients.
    Algaba A; Linares PM; Encarnación Fernández-Contreras M; Figuerola A; Calvet X; Guerra I; de Pousa I; Chaparro M; Gisbert JP; Bermejo F
    Inflamm Bowel Dis; 2014 Apr; 20(4):695-702. PubMed ID: 24562175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
    J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
    Vande Casteele N; Gils A; Singh S; Ohrmund L; Hauenstein S; Rutgeerts P; Vermeire S
    Am J Gastroenterol; 2013 Jun; 108(6):962-71. PubMed ID: 23419382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
    Singh N; Rosenthal CJ; Melmed GY; Mirocha J; Farrior S; Callejas S; Tripuraneni B; Rabizadeh S; Dubinsky MC
    Inflamm Bowel Dis; 2014 Oct; 20(10):1708-13. PubMed ID: 25153505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of anti-infliximab antibodies in Slovak IBD patients and its costs saving effect.
    Raffáč Š; Gombošová L; Gabzdilová J; Novotná L; Šajtyová K; Pekárová T; Kopolovets I; Tóth Š
    Neuro Endocrinol Lett; 2017 Nov; 38(Suppl1):5-9. PubMed ID: 29200248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.